New hope for myasthenia gravis: early ravulizumab treatment under study
NCT ID NCT06967480
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This study tests whether the drug ravulizumab can improve daily living activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR-positive). About 40 participants will receive treatment and be followed for 50 weeks. The goal is to see if early use of this medication can better control symptoms and reduce disease burden.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBergamo, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGBologna, Italy
-
Clinical Trial Site
RECRUITINGBologna, Italy
-
Clinical Trial Site
RECRUITINGBrescia, Italy
-
Clinical Trial Site
RECRUITINGFlorence, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGImperia, Italy
-
Clinical Trial Site
RECRUITINGLecco, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGMessina, Italy
-
Clinical Trial Site
RECRUITINGMilan, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGMilan, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGNaples, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGNovara, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGOrbassano, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGPadova, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGPalermo, Italy
-
Clinical Trial Site
RECRUITINGParma, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGPavia, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGPisa, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGRoma, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGSalerno, Italy
-
Clinical Trial Site
RECRUITINGSan Giovanni Rotondo, 71013, Italy
-
Clinical Trial Site
RECRUITINGSassari, Italy
-
Clinical Trial Site
NOT_YET_RECRUITINGTorino, Italy
Conditions
Explore the condition pages connected to this study.